Home' Australian Pharmacist : Australian Pharmacist December 2015 Contents Australian Pharmacist December 2015 I ©Pharmaceutical Society of Australia Ltd.
antipsychotic on PBS
From 1 November 2015, Australians
suffering from schizophrenia will have
a new treatment choice.
LATUDA (lurasidone), a new atypical
antipsychotic will be PBS listed
for the treatment of adults with
LATUDA has demonstrated
efficacy in the acute and long-term
treatment of schizophrenia.
LATUDA is well tolerated with
negligible effect on weight and
metabolic parameters including
total cholesterol, triglycerides &
LATUDA, available in 40mg and 80mg
tablet strengths, is taken once daily
Refer to the Product Information for
Servier Drug Information 1800 153 590 or
1. Australian Approved Product Information.
2. Meltzer H et al. Am J Psychiatry 2011; 168: 957-967.
3. Stahl S et al. J Clin Psychiatry 2013; 74: 507-15.
4. Loebel A et al. Schizophr Res 2013; 147: 95-102.
5. Loebel A et al. Schizophr Res 2013; 145: 101-9
6. Citrome L et al. Int Clin Psychopharmacol 2012; 27:
7. Mattingly G et al. Eur Neuropsychopharmacol. 2014; 24
Servier Laboratories (Australia) Pty. Ltd. 8 Cato Street
Hawthorn VIC 3122. Telephone 1800 153 590.
Australians are among the first in
the world to gain access to the new
dermal patch for the treatment of
actinic keratosis which is recognised
as the earliest stage of potentially
invasive squamous cell carcinoma
(SCC). Alacare 5-ala dermal patch with
photodynamic therapy (PDT) provides
a precisely targeted and effective
treatment for sun-spots with sustained
clinical outcomes and cosmetic results
that rated highly in trials. The Sun-spot
Awareness Report found that one in four
Australians (21%) aged 31 to 80 years
still do not check for signs of skin cancer,
because they ‘Never thought about it’
(46% of people who never check) or
are ‘Not sure what to look for’ (29%).
With a further 21% relying solely on
self-checking, nearly half the population
(46%) is at risk of missing skin cancer.
As many as 40–60% of Australians
– the highest rate in the world –
will develop actinic keratosis after the
age of 40.
Up to 10% of AK lesions may
progress to invasive SCC, which kills
around 520 Australians per year.
‘ The vast majority of SCC deaths are
preventable and early identification
and treatment of actinic keratosis,
especially as the population ages,
are critical to reduce the increasing
social and economic burden of non-
melanoma skin cancer in Australia,’
said Sydney dermatologist, Associate
Professor Stephen Shumack. ‘It’s
welcome news to have an additional
treatment option available in this
Alacare 5-ala dermal patch is not
Theracurmin Triple is concentrated to
three times the strength of the standard
Theracurmin. Curcumin is a powerful
anti-inflammatory agent shown to help
inhibit inflammation. This triple strength
product provides antioxidant support
and has been shown to help reduce joint
inflammation associated with arthritis.
According to a recent Orthopaedic
Surgery report, Curcumin, the
ancient spice found in Indian curries,
has showed increased promise in
arthritis and joint inflammation.
In Australia, there are 3.85 million
people affected by arthritis with current
trends suggesting that, by 2050,
seven million Australians will suffer
some form of arthritis.2
According to BioCeuticals, Theracurmin
Triple is highly bioavailable curcumin
concentrated to three times the strength
of the standard Theracurmin. It may help
down-regulate inflammatory mediators
and helps reduce joint inflammation
associated with arthritis. It also helps
reduce the oxidation of LDL cholesterol
and helps maintain healthy digestive
function and emulsify fats in the
1. Peddada KV, Peddada KV, Shukla SK, Mishra A, Verma V.
Role of Curcumin in Common Musculoskeletal Disorders: a
Review of Current Laboratory, 2015.
2. Painful realities: The economic impact of arthritis in
Australia 2007. (Report by Access Economics for Arthritis
Australia, 31 Jul 2007)
Links Archive Australian Pharmacist November 2015 Australian Pharmacist January 2016 Navigation Previous Page Next Page